KMT2A and leukemia: Using the RNA interference technique, HOXA9 has been shown to inhibit MLL rearrangement in MLL-rearranged leukemias, suggesting that targeting HOXA9 or its downstream signaling partners may present an effective therapeutic strategy [46].